Merck CEO Rob Davis told CNBC’s Jim Cramer that there’s more to the pharmaceutical giant than its lucrative cancer drug, ...

Merck and Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end ...

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts ...

Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before ...

China’s drug regulator approved Merck & Co.’s blockbuster HPV vaccine for use by men, opening a new untapped market for the ...

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Merck & Co., Inc.

(Bloomberg) -- Doctors may change how they treat liver cancer after drugs from AstraZeneca Plc and Merck & Co. helped some patients, marking the first treatment progress for them in decades.

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.